Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

ABSTRACT Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum...

Full description

Saved in:
Bibliographic Details
Main Authors: Lisa K. McNeil, Robert G. K. Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L. Harris, Thomas R. Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A. Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A. Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W. Mayer, Michael W. Pride, Kathrin U. Jansen, Annaliesa S. Anderson
Format: article
Language:EN
Published: American Society for Microbiology 2018
Subjects:
meningococcal antigen surface expression (MEASURE) assay
Neisseria meningitidis serogroup B
factor H binding protein
flow cytometry
vaccine
Microbiology
QR1-502
Online Access:https://doaj.org/article/c3d0bb482f1f4b6d8d47c0ace63109e3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/c3d0bb482f1f4b6d8d47c0ace63109e3

Similar Items